Tianjin Pharmaceutical da Ren Tang Group Ltd 2019 AR2
The report outlines the financial and operational performance of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited for the fiscal year 2019. The company achieved a revenue of approximately RMB 6,994 million, representing a 10% increase compared to the previous year. Key highlights include the implementation of a restricted stock equity incentive plan, the appointment of professional senior managers, and progress in academic marketing for key products like Suxiao Jiuxin Wan. Additionally, the company established a sustainability task force to oversee its environmental, social, and economic impacts, with a standalone sustainability report published in May 2020.
Company: Tianjin Pharmaceutical da Ren Tang Group Ltd
Sector: Manufacturing
Country: China
Year: 2019
Type: AR2
Pages: 232
Back to company
Tianjin Pharmaceutical da Ren Tang Group Ltd
Annual Report
The report outlines the financial and operational performance of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited for the fiscal year 2019. The company achieved a revenue of approximately RMB 6,994 million, representing a 10% increase compared to the previous year. Key highlights include the implementation of a restricted stock equity incentive plan, the appointment of professional senior managers, and progress in academic marketing for key products like Suxiao Jiuxin Wan. Additionally, the company established a sustainability task force to oversee its environmental, social, and economic impacts, with a standalone sustainability report published in May 2020.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available